Found: 1000
Select item for more details and to access through your institution.
Managing type 2 diabetes - beyond glycaemic control.
- Published in:
- Practice Nurse, 2018, v. 48, n. 10, p. 25
- By:
- Publication type:
- Article
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 22, p. 6860, doi. 10.3390/jcm13226860
- By:
- Publication type:
- Article
Dapagliflozin vs. empagliflozin in patients with chronic heart failure: a single-center registry analysis.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries.
- Published in:
- Molecular & Cellular Biochemistry, 2023, v. 478, n. 9, p. 1939, doi. 10.1007/s11010-022-04633-8
- By:
- Publication type:
- Article
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
- Published in:
- Molecular & Cellular Biochemistry, 2022, v. 477, n. 6, p. 1865, doi. 10.1007/s11010-022-04411-6
- By:
- Publication type:
- Article
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY.
- Published in:
- Clinical & Experimental Nephrology, 2024, v. 28, n. 6, p. 588, doi. 10.1007/s10157-024-02489-4
- By:
- Publication type:
- Article
Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED).
- Published in:
- Clinical & Experimental Nephrology, 2024, v. 28, n. 7, p. 629, doi. 10.1007/s10157-024-02467-w
- By:
- Publication type:
- Article
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 6, p. 1, doi. 10.1002/dmrr.3413
- By:
- Publication type:
- Article
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 9, p. 1504, doi. 10.1093/ndt/gfae032
- By:
- Publication type:
- Article
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 3, p. 414, doi. 10.1093/ndt/gfad183
- By:
- Publication type:
- Article
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 4, p. 894, doi. 10.1093/ndt/gfac198
- By:
- Publication type:
- Article
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 5, p. 847, doi. 10.1093/ndt/gfab330
- By:
- Publication type:
- Article
DIABETES. BASIC RESEARCH.
- Published in:
- Nephrology Dialysis Transplantation, 2021, v. 36, p. i365, doi. 10.1093/ndt/gfab093
- Publication type:
- Article
DIABETES. BASIC RESEARCH.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, p. 1293, doi. 10.1093/ndt/gfaa142
- Publication type:
- Article
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 5, p. 895, doi. 10.1093/ndt/gfz294
- By:
- Publication type:
- Article
Editorial: diabetic kidney disease: an update in recent clinical and basic research.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 5, p. 725, doi. 10.1093/ndt/gfz130
- By:
- Publication type:
- Article
FO051 Glycogen synthase kinases 3-α/β inhibition attenuates progression of diabetic kidney disease beyond treatment with metformin/Ramipril/empagliflozin.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, p. N.PAG, doi. 10.1093/ndt/gfz096.FO051
- By:
- Publication type:
- Article
Fournier's Gangrene and Sodium-Glucose Co-Transporter-2 Inhibitors: A Critical Combination in the Critical Care Unit.
- Published in:
- Journal of Critical & Intensive Care, 2024, v. 15, n. 2, p. 83, doi. 10.14744/dcybd.2024.4006
- By:
- Publication type:
- Article
A NOVEL VALIDATED STABILITY INDICATING METHOD FOR QUANTIFICATION OF EMPAGLIFLOZIN IN BULK AND MARKETED FORMULATION BY HPTLC APPLYING EXPERIMENTAL DESIGN APPROACH.
- Published in:
- Indian Drugs, 2023, v. 60, n. 6, p. 66, doi. 10.53879/id.60.06.13038
- By:
- Publication type:
- Article
Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices.
- Published in:
- Journal of Cardiovascular Electrophysiology, 2023, v. 34, n. 8, p. 1595, doi. 10.1111/jce.15996
- By:
- Publication type:
- Article
Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies.
- Published in:
- Journal of Diabetes Research, 2019, p. 1, doi. 10.1155/2019/2161085
- By:
- Publication type:
- Article
Case report of empagliflozin-induced euglycemic diabetic ketoacidosis.
- Published in:
- Journal of Emergency Medicine, Trauma & Acute Care, 2023, v. 2023, n. 2, p. 1, doi. 10.5339/jemtac.2023.19
- By:
- Publication type:
- Article
Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-51648-1
- By:
- Publication type:
- Article
Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-51949-5
- By:
- Publication type:
- Article
Long‐term follow up of a single case of metabolic surgery in an elderly Japanese patient with severe obesity.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Use of Oral Empagliflozin to Obtain Optimal Blood Sugar Levels for Conducting <sup>18</sup> F-FDG PET-CT in Patients with Hyperglycemia—A Pilot Study.
- Published in:
- World Journal of Nuclear Medicine, 2023, v. 22, n. 3, p. 191, doi. 10.1055/s-0043-1771283
- By:
- Publication type:
- Article
Effect of Sertraline as an Add-on Therapy in T2DM Patients with Comorbid Depression: An Open Label Randomized Controlled Trial.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2019, v. 23, n. 3, p. 357, doi. 10.4103/ijem.IJEM_67_19
- By:
- Publication type:
- Article
SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2019, v. 23, n. 2, p. 175, doi. 10.4103/ijem.IJEM_12_19
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2017, v. 21, n. 2, p. 286, doi. 10.4103/ijem.IJEM_517_16
- By:
- Publication type:
- Article
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2017, v. 21, n. 1, p. 245, doi. 10.4103/2230-8210.194341
- By:
- Publication type:
- Article
Empagliflozin: Not just a glorified diuretic.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions.
- Published in:
- Indian Journal of Endocrinology & Metabolism, 2015, v. 19, n. 3, p. 426, doi. 10.4103/2230-8210.152793
- By:
- Publication type:
- Article
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 4, p. 485, doi. 10.3390/pharmaceutics13040485
- By:
- Publication type:
- Article
A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 522, doi. 10.3390/ph17040522
- By:
- Publication type:
- Article
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 420, doi. 10.3390/ph17040420
- By:
- Publication type:
- Article
Empagliflozin Protects against Haloperidol Experimentally-Induced Ovarian Toxicity.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 2, p. 168, doi. 10.3390/ph16020168
- By:
- Publication type:
- Article
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 12, p. 1516, doi. 10.3390/ph15121516
- By:
- Publication type:
- Article
Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 2, p. 193, doi. 10.3390/ph15020193
- By:
- Publication type:
- Article
Empagliflozin—A New Chance for Patients with Chronic Heart Failure.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 1, p. 47, doi. 10.3390/ph15010047
- By:
- Publication type:
- Article
Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta‐analysis.
- Published in:
- Diabetology & Metabolic Syndrome, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13098-023-01182-y
- By:
- Publication type:
- Article
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy.
- Published in:
- Diabetology & Metabolic Syndrome, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13098-023-01061-6
- By:
- Publication type:
- Article
The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.
- Published in:
- Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00951-5
- By:
- Publication type:
- Article
Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study.
- Published in:
- Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00874-1
- By:
- Publication type:
- Article
New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation.
- Published in:
- Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00886-x
- By:
- Publication type:
- Article
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
- Published in:
- Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00801-4
- By:
- Publication type:
- Article
Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review.
- Published in:
- Patient Preference & Adherence, 2016, v. 10, p. 1999, doi. 10.2147/PPA.S85748
- By:
- Publication type:
- Article
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy.
- Published in:
- Therapeutics & Clinical Risk Management, 2023, v. 19, p. 133, doi. 10.2147/TCRM.S398163
- By:
- Publication type:
- Article
SGLT2 inhibitors and the changing landscape for treatment of diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.
- Published in:
- Therapeutics & Clinical Risk Management, 2017, v. 13, p. 603, doi. 10.2147/TCRM.S97619
- By:
- Publication type:
- Article
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.
- Published in:
- 2017
- By:
- Publication type:
- journal article